Kardigan (Nasdaq: KARD) completed enrollment of 156 participants in its Phase 2b KATALYST-AV trial evaluating ataciguat for aortic stenosis.
The company amended the protocol to assess the primary endpoint, aortic valve calcium, at Week 48, allowing more time to measure changes versus placebo. Baseline calcium measurements varied widely among the first 139 participants analyzed. Additional assessments will examine valve opening area and measures of heart structure and function.
An internal Week 24 interim analysis will evaluate progression rates and directional treatment trends. These analyses and a retrospective study of approximately 45,000 people will inform patient selection and endpoints for the planned Phase 3 trial. Kardigan expects a Phase 3 development update in the first half of 2027 and Week 48 topline results in the second half of 2027.
Kardigan (Nasdaq: KARD) appointed Kristin Reinke to its Board of Directors, effective September 29, 2026, to chair the Audit Committee. Doug Giordano, a founding board member, departed on the same date as part of what the company described as its public company evolution.
Reinke is vice president of finance at Google, where she leads the application of artificial intelligence to modernize and scale its finance organization. She has been on Google's finance leadership team since 2005 and also serves as an independent director and audit committee chair at Everly Health. She is a certified public accountant.
Kardigan (KARD) will present at two September 2026 healthcare investor conferences, including a webcast fireside chat.
The company will join the 2026 Cantor Global Healthcare Conference for a fireside chat on Wednesday, September 9, 2026, at 1:35 pm ET, and participate in 1x1 and small group meetings at Baird's 2026 Global Healthcare Conference on Tuesday, September 15, 2026. A live webcast and limited-time replay of the Cantor fireside chat will be available via the Investors & Media section of Kardigan’s website.
Kardigan (Nasdaq: KARD) reported second quarter 2026 results and updates on its three late-stage cardiovascular programs, danicamtiv, ataciguat and tonlamarsen. Cash, cash equivalents and investments were $660.7 million as of June 30, 2026, up from $335.5 million at year-end 2025, reflecting net proceeds from a June IPO with $460 million in aggregate gross proceeds.
Danicamtiv’s KINSHIP-DCM Phase 2b Cohort 1 enrollment has been completed and the Phase 3 portion is now enrolling, with Phase 2b topline data expected in 1H 2027. Ataciguat’s KATALYST-AV Phase 2b and tonlamarsen’s KARDINAL-ASH Phase 2 trials are ongoing, with topline data for both also targeted for 1H 2027. Q2 2026 research and development expenses rose to $56.4 million and net loss widened to $116.2 million, driven mainly by higher clinical spending and a $43.5 million change in fair value of contingent milestone liabilities.
Kardigan (Nasdaq: KARD), a clinical-stage precision cardiovascular therapeutics company, closed its initial public offering of 28,750,000 common shares, including 3,750,000 from the full underwriters’ option, at $16.00 per share.
Gross proceeds totaled $460 million before underwriting discounts and expenses, and the stock trades on the Nasdaq Global Market as KARD.
Kardigan (Nasdaq: KARD), a clinical-stage precision therapeutics company focused on cardiovascular diseases, priced its upsized IPO of 25,000,000 shares at $16 per share.
Gross proceeds are expected to be $400 million, with trading on the Nasdaq Global Market starting June 18, 2026, and closing expected June 22, 2026.